ADVISOR WATCHLIST
Patrick Shannon
Temple and Webster ( TPW ) is an online retailer of furniture , homewares , and other lifestyle products in Australia . Household goods spending in areas for furniture , floor coverings , houseware and textile goods increased 1.8 % in February , whilst overall spending fell 0.8 % month-on-month . I believe this area of retail spending is strongly correlated to Australia ’ s booming housing market , which has seen an abundance of first home buyers . I believe this area of retail spending to remain strong on this basis for the next 1 to 2 years . The company reported strong repeat customer numbers and effective marketing ( TV ads ) results in its 1H result presentation .
Designated Trading Representative Advisor – Equities PShannon @ burrell . com . au ( 07 ) 3006 7243
Shannon McShane
Cimic ( CIM ) provides engineering and construction services to the infrastructure , resources and property markets in Australia and internationally . While the company has been impacted by delays in project awards due to COVID , the outlook is positive with a $ 500 billion tender pipeline and work in hand of $ 30 billion , which is equivalent to about two years ’ worth of revenue . Cimic has exposure to government stimulus spending , with infrastructure having a significant role in the economic recovery from the pandemic .
Advisor - Gold Coast & Brisbane SMcShane @ burrell . com . au ( 07 ) 5583 7815
Shaun Minahan
CA , Associate - Senior Equities Advisor sminahan @ burrell . com . au ( 07 ) 5583 7800
Buy - Paradigm Biopharmaceuticals Ltd ( PAR )
Paradigm Biopharmaceuticals Ltd is an ASX listed biotechnology company focused on repurposing Pentosan Polysulfate Sodium ( PPS ), which is an FDA-approved drug that has a long track record of safely treating inflammation . Paradigm is repurposing PPS for a number of applications with a focus on treatment of osteoarthritis and concurrent sub-chondral bone marrow lesions . This drug is marketed as Zilosul .
The results from paradigm ’ s phase 2b clinical trial in knee osteoarthritis showed that subjects receiving IPPS showed on average a greater than 50 % reduction in pain . This data from the trial is consistent with the 183 patients recently treated under the therapeutic goods administration ( TGA ) special access scheme ( SAS ). Two weeks ago Paradigm made its first major submission for its Pivotal study in subjects with pain associated with Knee Osteoarthritis ( OA ), with the submission of its IND application to the US Food and Drug Administration ( FDA ).
Due to addictive nature of traditional opioid treatments and the effectiveness of Zilosul , paradigm estimates that the potential size of the market is $ 30 billion per annum . The company has a strong balance sheet with over A $ 70m cash . While the COVID-19 pandemic is likely to cause some minor delays , the company is well positioned and believes overall it is unlikely to have a material long term impact on the business .
Page 9 of 21